Topiramate, marketed under the trade name Topamax ®, is an anticonvulsant drug that was first approved in 1995 in the UK by Janssen Services.

Nuvig Therapeutics, Inc., initiates first human trial of NVG-2089 for treating inflammatory myopathies and severe autoimmune skin diseases.

Allopurinol, sold as Zyloprim®, is a drug that reduces uric acid in gout, kidney stones, and some cancers.

Atara Biotherapeutics Reports Filing a New Drug Application for ATA3219 Aimed at Treating Lupus Kidney Inflammation.

Aripiprazole, sold as Abilify Discmelt®, is an atypical antipsychotic for treating schizophrenia, bipolar disorder, depression, autism-related irritability, and Tourette's syndrome.

CalciMedica has received approval from the FDA to proceed with a Phase 2 study of Auxora™ in treating severe cases of acute kidney injury.

Guaifenesin, approved for medical use in Japan in 1949, is an expectorant medication found in numerous over-the-counter products.

Artax has initiated the dosing of the inaugural participant in their Phase 2a clinical study for Psoriasis, assessing the effects of compound AX-158.

Ketorolac Tromethamine, or Toradol®, is an NSAID used to treat moderate to severe pain.

Otsuka Reveals Key Outcomes from Final Stage Trial of AVP-786 for Managing Alzheimer’s-Related Dementia Agitation.

Zyprexa® (Olanzapine), an antipsychotic, is commonly used to treat schizophrenia, bipolar 1, and related agitation.

Puma Biotechnology has launched a Phase II study for Alisertib, targeting Small Cell Lung Cancer, named ALISCA-Lung1.